Advancing drug discovery for schizophrenia

Stephen R. Marder, Bryan Roth, Patrick F. Sullivan, Edward M. Scolnick, Eric J. Nestler, Mark A. Geyer, Daniel R. Welnberger, Maria Karayiorgou, Alessandro Guidotti, Jay Gingrich, Schahram Akbarian, Robert W. Buchanan, Jeffrey A. Lieberman, P. Jeffrey Conn, Stephen J. Haggarty, Amanda J. Law, Brian Campbell, John H. Krystal, Bita Moghaddam, Akira SawMarc G. Caron, Susan R. George, John A. Allen, Michelle Solis

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.

Original languageEnglish (US)
Pages (from-to)30-43
Number of pages14
JournalAnnals of the New York Academy of Sciences
Issue number1
StatePublished - Oct 2011
Externally publishedYes


  • GWAS
  • Genetics
  • Neuronal function
  • Schizophrenia
  • Small molecules
  • Therapeutics

ASJC Scopus subject areas

  • General Neuroscience
  • General Biochemistry, Genetics and Molecular Biology
  • History and Philosophy of Science


Dive into the research topics of 'Advancing drug discovery for schizophrenia'. Together they form a unique fingerprint.

Cite this